DE69232263D1 - Radikalfänger ("spin traps") zur behandlung von mit oxidation von lipiden und proteinen verbundenen erkrankungen - Google Patents

Radikalfänger ("spin traps") zur behandlung von mit oxidation von lipiden und proteinen verbundenen erkrankungen

Info

Publication number
DE69232263D1
DE69232263D1 DE69232263T DE69232263T DE69232263D1 DE 69232263 D1 DE69232263 D1 DE 69232263D1 DE 69232263 T DE69232263 T DE 69232263T DE 69232263 T DE69232263 T DE 69232263T DE 69232263 D1 DE69232263 D1 DE 69232263D1
Authority
DE
Germany
Prior art keywords
disorders
derivatives
spin
pbn
ischemia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69232263T
Other languages
English (en)
Other versions
DE69232263T2 (de
Inventor
M Carney
A Floyd
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oklahoma Medical Research Foundation
University of Kentucky Research Foundation
Original Assignee
Oklahoma Medical Research Foundation
University of Kentucky Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oklahoma Medical Research Foundation, University of Kentucky Research Foundation filed Critical Oklahoma Medical Research Foundation
Application granted granted Critical
Publication of DE69232263D1 publication Critical patent/DE69232263D1/de
Publication of DE69232263T2 publication Critical patent/DE69232263T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69232263T 1991-06-18 1992-06-18 Radikalfänger ("spin traps") zur behandlung von mit oxidation von lipiden und proteinen verbundenen erkrankungen Expired - Fee Related DE69232263T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71695291A 1991-06-18 1991-06-18
PCT/US1992/005194 WO1992022290A1 (en) 1991-06-18 1992-06-18 Use of spin trapping for the treatment of diseases associated with oxidation of lipids and proteins

Publications (2)

Publication Number Publication Date
DE69232263D1 true DE69232263D1 (de) 2002-01-17
DE69232263T2 DE69232263T2 (de) 2003-06-18

Family

ID=24880110

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69232263T Expired - Fee Related DE69232263T2 (de) 1991-06-18 1992-06-18 Radikalfänger ("spin traps") zur behandlung von mit oxidation von lipiden und proteinen verbundenen erkrankungen

Country Status (5)

Country Link
EP (1) EP0590072B1 (de)
AT (1) ATE209908T1 (de)
CA (1) CA2111836C (de)
DE (1) DE69232263T2 (de)
WO (1) WO1992022290A1 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681845A (en) * 1989-10-17 1997-10-28 Oklahoma Medical Research Foundation DMPO spin trapping compositions and methods of use thereof
US5455272A (en) * 1993-10-22 1995-10-03 Oklahoma Medical Research Foundation Spin trap nitronyl hindered phenols
US5405967A (en) * 1993-10-22 1995-04-11 Oklahoma Medical Research Foundation Spin-trap molecules 2-trifluoromethyl- of 5,5-dimethyl-1-dyrroline-N-oxide
US5488145A (en) * 1993-12-23 1996-01-30 Oklahoma Medical Research Foundation 2,4-disulfonyl phenyl butyl nitrone, its salts, and their use as pharmaceutical free radical traps
DE9408805U1 (de) * 1994-05-30 1994-09-01 Baur, Albert, 86845 Großaitingen Lautsprecher, insbesondere in Säulenform
JPH0870889A (ja) * 1994-09-02 1996-03-19 Tokyo Jiyoshi Ika Univ 臓器障害誘導因子の検出方法
ES2185797T3 (es) * 1995-09-11 2003-05-01 Aventis Pharma Inc Nitronas ciclicas y composiciones farmaceuticas que las contienen.
ATE263559T1 (de) * 1996-04-23 2004-04-15 Centaur Pharmaceuticals Inc Zubereitungen enhaltend eine nitroneverbindung für die verwendung bei der behandlung von uveitis
US5900227A (en) * 1996-06-17 1999-05-04 Oklahoma Medical Research Foundation Multicyclic nitrone spin trapping compositions
KR20000067915A (ko) * 1996-07-19 2000-11-25 센토르 파마슈티칼스, 인크. 푸란 니트론 화합물
TW429241B (en) * 1996-09-26 2001-04-11 Sumitomo Pharma Nitrone derivatives
US6096759A (en) * 1997-09-19 2000-08-01 Georgetown University Method for treating essential hypertension
US6046232A (en) * 1997-10-17 2000-04-04 Centaur Pharmaceuticals, Inc. α-aryl-N-alkylnitrones and pharmaceutical compositions containing the same
WO1999036415A1 (en) * 1998-01-16 1999-07-22 Centaur Pharmaceuticals, Inc. Thioether furan nitrone compounds
AU2226999A (en) * 1998-01-16 1999-08-02 Renovis, Inc. Thiophene nitrone compounds
US6255353B1 (en) * 1998-03-13 2001-07-03 Centaur Pharmaceuticals, Inc. Inhibition of angiogenesis
AU4184499A (en) 1998-05-19 1999-12-06 Renovis, Inc. Benzamide therapeutics for the treatment of inflammatory bowel disease
ATE271384T1 (de) * 1998-05-19 2004-08-15 Renovis Inc Arylnitron therapeutische mittel zur behandlung von entzündlichen darmerkrankungen
US6083989A (en) 1999-05-18 2000-07-04 Centaur Pharmaceuticals, Inc. Aryl nitrone therapeutics for the treatment of inflammatory bowel disease
WO1999059579A1 (en) * 1998-05-19 1999-11-25 Centaur Pharmaceuticals, Inc. Furan nitrone therapeutics for the treatment of inflammatory bowel disease
FR2780404B1 (fr) * 1998-06-26 2001-04-13 Adir Nouveaux derives de nitrone, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP1098873B1 (de) 1998-07-17 2004-05-26 Renovis, Inc. Alpha-(2-hydroxyphenyl)nitrone, diese enthaltenden pharmazeutische zubereitungen sowie deren verwendung zur behandlung von entzündungen
AU1917301A (en) * 1999-11-18 2001-05-30 Centaur Pharmaceuticals, Inc. Aryl nitrone therapeutics and methods for treating inflammatory bowel disease
WO2002065993A2 (en) 2001-01-08 2002-08-29 Centaur Pharmaceuticals, Inc. Use of aryl nitrone compounds in methods for treating neuropathic pain
US20050192281A1 (en) * 2003-10-14 2005-09-01 Kelly Michael G. Nitrone compounds, prodrugs and pharmaceuticals compositons of the same to treat human disorders
CN101128193B (zh) * 2004-12-22 2011-11-16 西巴特殊化学制品控股公司 抗自由基剂
DE602005022616D1 (de) 2004-12-22 2010-09-09 Basf Se Mittel gegen radikale
KR20080074901A (ko) * 2005-10-24 2008-08-13 시바 홀딩 인코포레이티드 산화성 물질의 보호
FR2902097A1 (fr) * 2006-06-13 2007-12-14 Univ Joseph Fourier Etablissem Nouveau procede de preparation de nitrones et de n-hydroxylamines comportant au moins un groupe hydroxyle, et produits tels qu'obtenus
US8420595B2 (en) 2006-07-25 2013-04-16 Oklahoma Medical Research Foundation Methods for treating acute acoustic trauma
AU2009214727B2 (en) 2008-02-12 2014-12-11 Tosk, Incorporated Doxorubicin adjuvants to reduce toxicity and methods for using the same
JP6654142B2 (ja) * 2014-03-07 2020-02-26 ダウ グローバル テクノロジーズ エルエルシー ニトロン化合物及びパーソナルケアにおけるその使用
JP2017515814A (ja) 2014-05-12 2017-06-15 ダウ グローバル テクノロジーズ エルエルシー ニトロン化合物及びパーソナルケアにおけるその使用
BR112016029693B1 (pt) 2014-06-30 2021-08-03 Dow Global Technologies Llc Composição para cuidado pessoal compreendendo nitronas poliméricas, e, métodos para a inibição da degradação do colágeno na pele, e para reduzir os sinais visíveis do envelhecimento
BR112017020038B1 (pt) 2015-03-20 2021-03-09 Dow Global Technologies Llc método para inibir a oxidação de uma gordura insaturada
US10130574B2 (en) 2015-03-20 2018-11-20 Dow Global Technologies Llc Nitrone inhibition of oxidation of unsaturated fats

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3834073A (en) * 1971-05-03 1974-09-10 Scm Corp Phenyl nitrone derivatives useful as seed protectants
US4153722A (en) * 1977-10-06 1979-05-08 William H. Rorer, Inc. Method of treatment
AU1107888A (en) * 1986-12-29 1988-07-27 Pharmacia Ab Nitroxide compounds for the preparation of a pharmaceutical composition intended for the prophylaxis and treatment of ischemic cell damage
AU1362488A (en) * 1987-01-28 1988-08-24 Peter H. Proctor Topical composition and method for stimulating hair growth with stable free radicals
EP0496796B1 (de) * 1989-10-17 1994-08-31 Oklahoma Medical Research Foundation Verfahren und zubereitungen zur hemmung von mit oxidativer schädigung assoziierten krankheiten
US5036097A (en) * 1989-10-17 1991-07-30 Oklahoma Medical Research Foundation Phenylbutyl nitrone compositions and methods for prevention of gastric ulceration

Also Published As

Publication number Publication date
CA2111836A1 (en) 1992-12-23
AU2261492A (en) 1993-01-12
DE69232263T2 (de) 2003-06-18
ATE209908T1 (de) 2001-12-15
CA2111836C (en) 2006-08-29
AU672364B2 (en) 1996-10-03
EP0590072B1 (de) 2001-12-05
EP0590072A1 (de) 1994-04-06
WO1992022290A1 (en) 1992-12-23

Similar Documents

Publication Publication Date Title
DE69232263D1 (de) Radikalfänger (&#34;spin traps&#34;) zur behandlung von mit oxidation von lipiden und proteinen verbundenen erkrankungen
PT740650E (pt) Co-farmacos como um metodo de administracao controlada de farmacos
ATE399553T1 (de) Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen
DE69230112T2 (de) Fortschrittliches arzneistoffabgabesystem und verfahren zur behandlung von psychiatrischen, neurologischen und anderen erkrankungen mit carbamazepin
TR199801180T2 (xx) Aneljestik etkiye sahip yeni bile�ikler.
DE69213814D1 (de) Melatoninderivate zur Behandlung von Schlafstörungen und zur Pre-Anästhesie
BG101118A (en) Therapeutical compounds
ATE170077T1 (de) Verfahren zur behandlung von krebs durch kombinationstherapie mit 2&#39;- halomethylidenderivaten und einem s- oder m-phase spezifischen antineoplastischen wirkstoff
RU2001116077A (ru) Способ лечения церебральных ишемий, а также применение эритропоэтина или производных эритропоэтина для лечения церебральных ишемий
ATE197670T1 (de) Parenterales busulfan zur behandlung von malignen krankheiten
ATE198550T1 (de) Verwendung von weihrauch zur behandlung der alzheimer-krankheit
BR9813318A (pt) Processo de tratamento de tumores e degeneração macular em paciente humano ou veterinário, composição farmacêutica para tratamento de tumores e degeneração macular em um paciente humano ou veterinário
RU95101385A (ru) Продукты, содержащие g-csf и tnf связующие протеина
DE58901002D1 (de) Mittel mit zerstoerender wirkung auf maligne tumore, verfahren zu dessen herstellung und praeparation zur anwendung in der therapie von krebskranken.
DE60031016D1 (de) Verwendung von Antiseptika zur Herstellung von Arzneimitteln zur Prophylaxe und Behandlung von Entzündungen im Korperinneren des Menschen
DE3787477D1 (de) Nasal applizierbares Arzneimittel, Verfahren zu seiner Herstellung und seine Verwendung.
DE58904722D1 (de) Arzneimittelzubereitung aus esterderivaten des hecogenins und dessen verwendung zur behandlung von benigner prostatahyperplasie.
ATE89737T1 (de) Behandlung von leukozytstoerungen mit gm-csf.
ATE316379T1 (de) Oxyhuminsäure und ihre verwendung zur behandlung von verschiedenenen störungen
NO810480L (no) Anologifremgangsmaate for fremstilling av terapeutisk aktive 1,3,4-oksadiazolylfenol-derivater
DE69621786T2 (de) Aminotetralinderivat zur behandlung von herzkreislauferkrankung
DE68901172D1 (de) (-)-2-pyrazolinverbindung, deren optischen aufspaltung und therapeutisches agens zur behandlung von zerebralen gefaesskrankheiten, diese verbindung als aktives ingredient enthaltend.
DE69009765D1 (de) Kynurensäurederivate, deren herstellung und diese enthaltende pharmazeutische zusammensetzungen.
ATE152911T1 (de) Verwendung von bilobalid und deren derivate zur behandlung von infektionen bei menschen und für eine solche anwendung geeignete pharmazeutische zusammensetzung
ATE335494T1 (de) Verwendung von n-glycolneuraminsäure und deren derivaten zur herstellung eines medikaments zur behandlung von hiv-infektionen

Legal Events

Date Code Title Description
8332 No legal effect for de
8370 Indication related to discontinuation of the patent is to be deleted
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee